- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00226824
Safety Study of Galantamine in Tic Disorders
Pilot Examination of Galantamine in the Management of Tic Disorders
Study Overview
Status
Intervention / Treatment
Detailed Description
Modulation of cholinergic activity is a growing focus in neurologic therapeutics especially for dementing disorders such as Alzheimer disease. Treatment with the recently developed cholinesterase inhibitor, galantamine, has demonstrated significant improvement with few issues related to tolerability. In addition to inhibiting the activity of acetylcholinesterase, galantamine also modulates the activity of nicotinic cholinergic receptors by an allosteric mechanism. As a result, galantamine therapy may be beneficial when the response to other agents has been limited.
Cholinesterase inhibitor therapy has been reported to improve motor tics in children with TS refractory to more traditional therapies. Symptoms of co-morbid behavioral disorders, primarily inattention, were also improved. Cholinergic modulation appears a promising avenue for managing tic disorders.
Men and women (18 - 50 years of age) fulfilling DSM IV criteria for the diagnosis of chronic motor tic disorder, chronic vocal tic disorder or Tourette Syndrome and experiencing suboptimal control of tics on current therapy will be enrolled into this open label evaluation of galantamine. A total of 6 visits will be required over 22 weeks. Participants will follow a standard 4 week titration schedule achieving 12 mg bid after 8 weeks. They will maintain at 12 mg bid, or the maximum tolerated dose, for a further 8 weeks and then be withdrawn from therapy. The difference in tic severity prior to and upon completion of therapy will be examined. The impact of treatment upon obsessions/compulsions, attention/concentration, depression, anxiety and quality of life will also be determined.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
Albany, New York, United States, 12205
- Parkinson's Disease and Movement Disorders Center of Albany Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- DSM IV criteria for the diagnosis of Tourette's syndrome, chronic motor or chronic vocal tic disorder
- Accepted method of birth control
Exclusion Criteria:
- Preganancy or nursing
- Unstable medical illness
- Unstable psychiatric illness
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Treatment related adverse experience
|
Severity Score of the Yale Global Tic Severity Scale
|
Secondary Outcome Measures
Outcome Measure |
---|
Hamilton Rating Scale for Depression
|
Yale-Brown Obsessive-Compulsive Survey
|
Connors Adult Attention Deficit Hyperactivity Rating Scale
|
Hamilton Rating Scale for Anxiety
|
Short Form 36
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Donald S Higgins, M.D., Parkinson's Disease and Movement Disorder Center of Albany Medical Center
Publications and helpful links
General Publications
- Hoopes SP. Donepezil for Tourette's disorder and ADHD. J Clin Psychopharmacol. 1999 Aug;19(4):381-2. doi: 10.1097/00004714-199908000-00019. No abstract available.
- Wilens TE, Biederman J, Wong J, Spencer TJ, Prince JB. Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. J Child Adolesc Psychopharmacol. 2000 Fall;10(3):217-22. doi: 10.1089/10445460050167322.
- Hayslett RL, Tizabi Y. Effects of donepezil on DOI-induced head twitch response in mice: implications for Tourette syndrome. Pharmacol Biochem Behav. 2003 Dec;76(3-4):409-15. doi: 10.1016/j.pbb.2003.08.015.
- Burt T. Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents. Curr Psychiatry Rep. 2000 Dec;2(6):473-8. doi: 10.1007/s11920-000-0005-7.
Study record dates
Study Major Dates
Study Start
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Heredodegenerative Disorders, Nervous System
- Neurodevelopmental Disorders
- Disease
- Tourette Syndrome
- Tic Disorders
- Tics
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Parasympathomimetics
- Galantamine
Other Study ID Numbers
- GAL-EMR-4017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tourette's Syndrome
-
Weill Medical College of Cornell UniversityUniversity of California, Los Angeles; University of Wisconsin, MilwaukeeCompletedTourette's Syndrome | Tourette's Disorder | Tourette Disorder | Gilles de la Tourette Syndrome | Tourette's Disease | Tourette Disease | Tic Disorder, Combined Vocal and Multiple Motor | Multiple Motor and Vocal Tic Disorder, Combined | Gilles de La Tourette's Disease | Gilles De La Tourette's Syndrome | Combined... and other conditions
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedTourette's Disorder (TD)United States, Canada, Hungary
-
The University of Western AustraliaSir Charles Gairdner Hospital; Perron Institute for Neurological and Translational...WithdrawnTourette's SyndromeAustralia
-
Psyadon PharmaUnknown
-
University of FloridaBristol-Myers SquibbTerminated
-
University Hospital, Clermont-FerrandCompletedGilles de la Tourette's SyndromeFrance
-
Groupe Hospitalier Pitie-SalpetriereInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Ministry of Health, ItalyCompletedTourette Syndrome | Tourette's Syndrome | Tourette Disorder | Gilles de la Tourette SyndromeItaly
-
China Medical University HospitalBened Biomedical Co., Ltd.RecruitingTourette's SyndromeTaiwan
-
Bausch Health Americas, Inc.Withdrawn
Clinical Trials on galantamine
-
Yale UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Samsung Medical CenterJanssen Korea, Ltd., KoreaCompleted
-
Ludwig-Maximilians - University of MunichUnknownAlzheimer's DiseaseGermany
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH); Massachusetts General HospitalCompletedBipolar DisorderUnited States
-
The University of Texas Health Science Center,...Completed
-
Janssen Pharmaceutical K.K.CompletedAlzheimer's DiseaseJapan
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedAlzheimer Disease
-
Actavis Inc.Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFrontotemporal Dementia | Pick Complex